Extramedullary Disease in Acute Promyelocytic Leukemia

References

• Hillestad L. K. Acute Promyelocytic Leukaemia. Acta Med Scandin 1957; 159: 189–95
   PubMed Web of Science ®Google Scholar
• Bernard J., Mathe G., Boulay J., Ceora B. La leucose aigue a promyelocytes Etude portant sur 20 obsevations. J Suisee de Medecine 1959; 23: 604–610
   Google Scholar
• Stone R. M., Mayer R. J. The unique aspects of acute promyelocytic leukemia. J. Clin. Oncol. 1990; 8: 1913–1921
   PubMed Web of Science ®Google Scholar
• Avvisati G., Ten Cate J. W., Mandelli F. Acute promyelocytic leukaemia. Br. J. Haematol 1992; 81: 315–320
   PubMed Web of Science ®Google Scholar
• Bennett J., Catovsky D., Daniel M. T., Flandrin G., Galton D. A. G., Gralnick N. R., Sultan C. [French‐American‐British (FAB) cooperative group]. Proposals for the classification of the acute leukaemias. Br. J. Haematol. 1976; 33: 451–458
   PubMed Web of Science ®Google Scholar
• Castoldi G. L., Liso V., Specchia G., Tomasi P. Acute promyelocytic leukemia: morphological aspects. Leukemia 1994; 8(Sup. 2)s27–s32
   PubMedGoogle Scholar
• Golomb H. M., Rowley J. D., Vardiman J. W., Testa J. R., Butler A. “Microgranular” acute promyelocytic leukemia: a distinct clinical, ultrastructural and cytogenetic entity. Blood 1980; 55: 253–259
   PubMed Web of Science ®Google Scholar
• Biondi A., Luciano A., Bassan R., Mininni D., Specchia G., Lanzi E., Castagna S., Cantu‐Rajnoldi A., Liso V., Masera G., Barbui T., Rambaldi A. CD2 expression in acute promyelocytic leukemia is associated with microgranular morphology (FAB M3v) but not with any PMLbreakpoint. Leukemia 1995; 9: 1461–1466
   PubMed Web of Science ®Google Scholar
• McKenna R. W., Parkin J., Bloomfield C. D., Sundberg R. D., Brunning R. D. Acute promyelocytic leukaemia: a study of 39 cases with identification of a hyperba‐sophilic variant. Br. J. Haematol. 1982; 50: 201–214
   PubMed Web of Science ®Google Scholar
• Yu R. ‐Q., Huang W., Chen S. ‐J., Jiang S. ‐D., Chen Z. A case of acute eosinophilic granulocytic leukemia with PML‐RAR alpha fusion gene expression and response to all‐trans retinoic acid. Leukemia 1997; 609–611, volume
   PubMed Web of Science ®Google Scholar
• Rowley J. D., Golomb H. M., Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 1977; 1: 549–550
   PubMed Web of Science ®Google Scholar
• Larson R. A., Kondo K., Vardiman J. W., Butler A. E., Golomb H. M., Rowley J. D. Evidence for a 15; 17 translocation in every patient with acute promyelocytic leukemia. Am. J. Med. 1984; 76: 827–841
   PubMed Web of Science ®Google Scholar
• Tallman M. S., Kwaan H. C. Reassessing the hemostatic disorder associated with acute promyelocytc leukemia. Blood 1992; 79: 543–553
   PubMed Web of Science ®Google Scholar
• Rodeghiero F., Castaman G. The pathophysiology and treatment of hemorrhagic syndrome of acute promy‐elocytic leukemia. Leukemia 1994; 8(Sup. 2)s20–s26
   PubMedGoogle Scholar
• Breitman T. R., Collins S. J., Keene B. R. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood 1981; 57: 1000–1004
   PubMed Web of Science ®Google Scholar
• Chomienne C., Ballerini P., Balitrand N., Daniel M. T., Fenaux P., Castaigne S., Degos L. All trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies structure function relationship. Blood 1990; 76: 1710–1717
   PubMed Web of Science ®Google Scholar
• Huang M. ‐E., Ye Y. ‐C., Chen S. ‐R., Chai J. ‐R., Lu J. ‐X., Zhoa L., Gu L. ‐J., Wang Z. ‐Y. Use of all‐trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572
   PubMed Web of Science ®Google Scholar
• Borrow J., Goddard A. D., Sheer D., Solomon E. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990; 249: 1577–1580
   PubMed Web of Science ®Google Scholar
• de Thé H., Chomienne C., Lanotte M., Degos L., Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature 1990; 347: 558–561
   PubMed Web of Science ®Google Scholar
• de Thé H., Lavau C., Marchio A., Chomienne G., Degos L., Dejean A. The PML‐RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66: 675–684
   PubMed Web of Science ®Google Scholar
• Alcalay M., Zangrilli D., Pandolfi P. P., Longo L., Men‐carelli A., Giacomucci A., Rocchi M., Biondi A., Ram‐baldi A., Lo Coco F., Diverio D., Donti E., Grignani F., Pelicci P. G. Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor α locus. Proc. Natl. Acad. Sci. USA 1991; 88: 1977–1981
   PubMed Web of Science ®Google Scholar
• Goddard A. D., Borrow J., Freemont P. S., Solomon E. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science 1991; 254: 1371–1374
   PubMed Web of Science ®Google Scholar
• Kakizuka A., Miller W. H., Umesono K., Warrell R. P., Frankel S. R., Murty V. V.V. S., Dmitrovsky E., Evans R. M. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. Cell 1991; 66: 663–674
   PubMed Web of Science ®Google Scholar
• Miller W. H., Kakizuka A., Frankel S. R., Warrell R. P., DeBlasio A., Levine K., Evans R., Dmitrovsky E. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor α clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 1992; 89: 2694–2698
   PubMed Web of Science ®Google Scholar
• Pandolfi P. P. PML, PLZF and NPM genes in the molecular pathogenesis of acute promyelocytic leukemia. Haematologica 1996; 81: 472–482
   PubMedGoogle Scholar
• Rosenauer A., Raelson J. V., Nervi C., Eydoux P., DeBlasio A., Miller W. H. Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild‐type retinoid receptors in retinoid‐resistant acute promyelocytic leukemia cell‐lines. Blood 1996; 88: 2671–2682
   PubMed Web of Science ®Google Scholar
• He L. ‐Z., Guidez F., Tribioli C., Peruzzi D., Ruthardt M., Zelent A., Pandolfi P. P. Distinct interactions of PML‐RARα and PLZF‐RARα with co‐repressors determine differential responses to RA in APL. Nat. Genet. 1998; 18: 126–134
   PubMed Web of Science ®Google Scholar
• Lin R. J., Nagy L., Inoue S., Shao W., Miller W. H., Evans R. M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998; 391: 811–814
   PubMed Web of Science ®Google Scholar
• Grignani F., De Matteis S., Nervi C., Tomassoni L., Gel‐metti V., Cioce M., Fanelli M., Ruthardt M., Ferrara F. E., Zamir I., Seiser C., Grignani E., Lazar M. A., Minucci S., Pelicci P. G. Fusion proteins of the retinoic acid receptor‐α recruit histone deacetylase in acute promyelocytic leukaemia. Nature 1998; 391: 815–818
   PubMed Web of Science ®Google Scholar
• Ding W., Li Y. ‐P., Nobile L. M., Grills G., Carrera I., Paietta E., Tallman M. S., Wiemik P. H., Gallagher R. E. Leukemic cellular retinoic acid resistance and missense mutations in the PML‐RARα fusion gene after relapse of acute pronyelocytic leukemia from treatment with all‐trans retinoic acid and intensive chemotherapy. Blood 1998; 92: 1172–1183
   PubMed Web of Science ®Google Scholar
• Guidez F., Ivins S., Zhu J., Soderstrom M., Waxman S., Zelent A. Reduced retinoic acid sensitivities of nuclear receptor corepressor binding to PML‐and RARA underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 1998; 91: 2634–2642
   PubMed Web of Science ®Google Scholar
• Chen S. ‐J., Zelent A., Tong J. ‐H., Yu H. ‐Q., Wang Z. ‐Y., Derré J., Berger R., Waxman S., Chen Z. Rearrangements of the retinoic acid receptor alpha and promyelocytic zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukaemia. J. Clin. Invest. 1993; 91: 2260–2267
   PubMed Web of Science ®Google Scholar
• Chen Z., Brand N. J., Chen A., Chen S. ‐J., Tong J. ‐H., Wang Z. ‐Y., Waxman S., Zelent A. Fusion between a novel Krüppel‐like zinc finger gene and the retinoic acid receptor‐α locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J. 1993; 12: 1161–1167
   PubMed Web of Science ®Google Scholar
• Licht J. D., Chomienne C., Goy A., Chen A., Scott A. A., Head D. R., Michaux J. L., Wu Y., DeBlasio A., Miller W. H., Zelenetz A. D., Willman C. L., Chen Z., Chen S. ‐J., Zelent A., Macintyre E., Veil A., Cortes J., Kantarjian H., Waxman S. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 1995; 85: 1083–1094
   PubMed Web of Science ®Google Scholar
• Wells R. A., Catzavelos C., Kamel‐Reid S. Fusion of retinoic acid receptor α to NUMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukemia. Nat. Genet. 1997; 17: 109–113
   PubMed Web of Science ®Google Scholar
• Redner R. L., Rush E. A., Faas S., Rudert W. A., Corey S. J. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin‐retinoic acid receptor fusion. Blood 1996; 87: 882–886
   PubMed Web of Science ®Google Scholar
• Redner R. L., Corey S. J., Rush E. A. Differentiation of t(5;17) variant acute promyelocytic leukemia blasts by all‐transretinoic acid. Leukemia 1997; 11: 1014–1016
   PubMed Web of Science ®Google Scholar
• Castaigne S., Chomienne C., Daniel M. T., Ballerini P., Berger R., Fenaux P., Degos L. All‐trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 76: 1704–1709
   PubMed Web of Science ®Google Scholar
• Lo Coco F., Diverio D., Pandolfi P. P., Biondi A., Rossi V., Avvisati G., Rambaldi A., Arcese W., Petti M. C., Meloni G., Mandelli F., Grignani E., Masera G., Barbui T., Pelicci P. G. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 1992; 340: 1437–1438
   PubMed Web of Science ®Google Scholar
• Fenaux P., Castaigne S., Chomienne C., Dombret H., Degos L. All trans retinoic acid treatment for patients with acute promyelocytic leukemia. Leukemia & Lymphoma 1992; 6: 64–66
   Google Scholar
• Frankel S. R., Eardley A., Lauwers G., Weiss M., Warrell R. P. The “retinoic acid syndrome” in acute promyelocytic leukemia. Ann. Intern. Med. 1992; 117: 292–296
   PubMed Web of Science ®Google Scholar
• Vahdat L., Maslak P., Miller W. H., Eardley A., Heller G., Scheinberg D. A., Warrell R. P. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low‐dose chemotherapy, PML‐RARα isoform, and CD13 expression in patients treated with all‐trans retinoic acid. Blood 1994; 84: 3843–3849
   PubMed Web of Science ®Google Scholar
• Mandelli F., Diverio D., Avvisati G., Luciano A., Barbui T., Bernasconi C., Broccia G., Ceeri R., Falda M., Fioritoni G., Leoni F., Liso V., Petti M. C., Rodeghiero F., Saglio G., Vegna M. L., Visani G., Jehn U., Willemze R., Muus P., Pelicci P. G., Biondi A., Lo Coco F. Molecular remission in PML/RARα‐positive acute promyelocytic leukemia by combined all‐trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997; 90: 1014–1021
   PubMed Web of Science ®Google Scholar
• Burnett A. K., Grimwade D., Solomon E., Wheatley K., Goldstone A. H. Presenting white cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all‐(transretinoic acid: Result of the randomised MRC trial. 1998, Submitted for publication
   Google Scholar
• Dombret H., Scrobohaci M. L., Ghorra P., Zini J. M., Daniel M. T., Castaigne S., Degos L. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all‐trans retinoic acid treatment. Leukemia 1993; 7: 2–9
   PubMed Web of Science ®Google Scholar
• Fenaux P., Chastang C., Castaigne S., Archimbaud E., Sanz M., Link H., Guerci A., Fegueux N., Zittoun R., Stoppa A. M., Travade P., Lamy T., Maloisel E., Sadoun A., San Miguel J., Veil A., Rayon C., Conde E., Fey M., Bordessoule D., Ganser A., Bowen D., Dreyfus F., Huguet E., Tilly H., Guy H., Auzanneau G., Chomienne C., Degos L. Treatment of newly diagnosed acute promyelocytic leukemia (APL) with all‐transretinoic acid (ATRA) followed by intensive chemotherapy (CT). Updated results of the European group. Blood 1994; 84(Sup. 1)379a
   Google Scholar
• Tallman M. S., Andersen J. W., Schiffer C. A., Appelbaum F. R., Feusner J. H., Ogden A., Shepherd L., Willman C., Bloomfield C. D., Rowe J. M., Wiernik P. H. All‐trans‐retinoic acid in acute promyelocytic leukemia. N. Engl. J. Med. 1997; 337: 1021–1028
   PubMed Web of Science ®Google Scholar
• Byrd J. C., Edenfield W. J., Shields D. J., Dawson N. A. Extramedullar myeloid cell tumors in acute non‐lymphocytic leukemia: A clinical Review. J Clin. Oncol. 1995; 13: 1800–1816
   PubMed Web of Science ®Google Scholar
• Tallman M. S., Hakimian D., Shaw J. M., Lissner G. S., Russell E. J., Variakojis D. Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia. J Clin. Oncol. 1993; 11: 690–697
   PubMed Web of Science ®Google Scholar
• Kantarjian H., Keating M. J., Walters R. S., Estey E. H., McCredie K. B., Smith K. B., Dalton T. L., Cork W. T., Trujillo J. M., Freireich E. J. Acute promyelocytic leukemia. MD Anderson Hospital experience. Am J Med 1986; 80: 789–797
   PubMed Web of Science ®Google Scholar
• Marra R., Stori S., Pagano L., Fioritoni G., Rabitti C., Sica S., Leone G., Torlatono G., Bizzi B. Central nervous system acute promyelocytic leukemia. A report of three cases. Haematologia 1989; 22: 195–199
   PubMedGoogle Scholar
• Solano Vercet C., Escudero A., Femandez‐Ranada J. M. Meningeal relapse in acute promyelocytic leukemia. Acta haemat 1983; 70: 137–138
   PubMed Web of Science ®Google Scholar
• Brown D. M., Kimura A. E., Ossoinig K. C., Weiner G. J. Acute promyelocytic leukaemia of optic nerve treated with oral trans retinoic acid. Opthalmology 1992; 99: 1463–1467
   PubMed Web of Science ®Google Scholar
• Ajarim D. S., Santhosh C. R., Higgy K. E., Saghir N. S., Almomen A. K., Shipkey F. D. Granulocytic sarcoma of the thymus in acute promyelocytic leukaemia. Clin Lab Haematol 1990; 12: 97–99
   PubMedGoogle Scholar
• Kubonishi I., Ohtsuki Y., Machida K. Granulocytic sarcoma presenting as a mediastinal tumor. Am J Clin Path 1984; 82: 730–734
   PubMed Web of Science ®Google Scholar
• Haznedaroglu I. C., Ustundag Y., Benekli M., Savas M. C., Safali M., Dundar S. V. Isolated gingival relapse during complete haematological remission in acute promyelocytic leukaemia. Acta Haematologica 1995; 93: 54–55
   PubMed Web of Science ®Google Scholar
• Lederman C., Weisberger J., Seiter K., Feldman E. Differentiation of extramedullary acute promyelocytic leukemia by ATRA. Leukemia & Lymphoma 1995; 18: 189–193
   PubMed Web of Science ®Google Scholar
• Selleri C., Pane E., Notaro R., Catalano L., Santoro L. E. F., Luciano L., Frigeri F., Salvatore F., Rotoli B. All trans retinoic acid responsive skin relapses of acute promyelocytic leukaemia followed by ATRA induced pseudotumour cerebri. Br. J. Haematol 1996; 92: 937–940
   PubMed Web of Science ®Google Scholar
• Allford S., Grimwade D., Langabeer S., Duprez E., Saurin A., Chatters S., Walker H., Roberts P., Rogers J., Bain B., Patterson K., McKernan A., Freemont P., Solomon E., Burnett A., Goldstone A., Linch D. Identification of the t(15;17) in the absence of APL morphology: evaluation of the role of molecular screening for the PML/RARα rearrangement in newly diagnosed AML. 1998, Submitted
   Google Scholar
• Miundi J., Frankel S., Huselton C., DeGrazia E., Garland W., Young C., Warrell R. Clinical pharmacology of oral all trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Research 1992; 52: 2138–2142
   PubMed Web of Science ®Google Scholar
• Gallagher R. E., Willman C. L., Slack J. L., Andersen J. W., Li Y., Viswanatha D., Bloomfield C. D., Appelbaum F. R., Schiffer C. A., Tallman M. S., Wiernik P. H. Association of PML‐RARA fusion mRNA type with pre‐treatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood 1997; 90: 1656–1663
   PubMed Web of Science ®Google Scholar
• Evans G., Grimwade D., Prentice H. G., Simpson C. N. Central nervous system relapse in acute promyelocytic leukaemia in patients treated with all‐trans retinoic acid. Br. J. Haematology 1997; 98: 437–439
   PubMed Web of Science ®Google Scholar
• Grimwade D., Howe K., Langabeer S., Davies L., Oliver E., Walker H., Swirsky D., Wheatley K., Goldstone A., Burnett A., Solomon E. Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M. R. C. ATRA trial. Br. J. Haematol. 1996; 94: 557–573
   PubMed Web of Science ®Google Scholar
• Currie J., Chee Y. L., Culligan D. Central nervous system relapse in acute promyelocytic leukaemia treated with ATRA. Br J. Haematol 1997; 99: 469–469
   PubMed Web of Science ®Google Scholar
• Avvisati G., Lo Coco E., Diverio D., Falda M., Ferrara F., Lazzarino M., Russo D., Petti M. C., Mandelli F. AIDA (All trans retinoic acid+Idarubicin) in Newly Diagnosed Acute Promyelocytic Leukemia: A Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Pilot Study. Blood 1996; 88: 1390–1398
   PubMed Web of Science ®Google Scholar
• Diverio D., Rossi V., Avvisati G., De Santis S., Pistilli A., Pane F., Saglio G., Martinelli G., Petti M. C., Santoro A., Pelicci P. G., Mandelli E., Biondi A., Lo Coco F. Early detection of relapse by prospective polymerase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA‐AIEOP multicenter “AIDA” trial. Blood 1998; 92: 784–9, 1998
   PubMed Web of Science ®Google Scholar
• Martino B., Vincelli I., Marino A., Comis M., Ronco F., Nobile F. Meningeal relapse in a patient with acute promyelocytic leukaemia treated with all trans retinoic acid. Br J. Haematol 1998; 100: 606–607
   PubMed Web of Science ®Google Scholar
• Giralt S., O'Brien S., Weeks E., Luna M., Kantarjian H. Leukemia Cutis in acute promyelocytic leukemia: A report of three cases after treatment with all trans retinoic acid. Leukemia & Lymphoma 1994; 14: 453–456
   PubMed Web of Science ®Google Scholar
• Thomas X., Fiere D., Archimbaud E. Persistence of retinoic acid sensitivity in relapsed acute promyelocytic leukemia with extramedullary involvement. Leukemia 1994; 8: 520–521
   PubMed Web of Science ®Google Scholar
• Weiss M. A., Warrell R. P. Two cases of extramedullary acute promyelocytic leukaemia. Cancer 1994; 74: 1882–1886
   PubMed Web of Science ®Google Scholar
• Nagao K., Kikuchi A., Kawai Y., Kizaki M., Ikeda Y., Nishikawa T. Skin infiltration in acute promyelocytic leukaemia. Dermatology 1997; 194: 168–171
   PubMed Web of Science ®Google Scholar
• Fenaux P., Chastang C., Sanz M., Thomas X., Dombret H., Link H., Guerci A., Fegueux J., San Miguel J., Rayon C., Zittoun R., Gardin C., Maloisel F., Fey M., Travade P., Reiffers J., Stamatoulas A., Stoppa A. M., Caillot D., Lefrere F., Hayat M., Castaigne S., Chomienne C., Degos L. ATRA followed by chemotherapy (CT) vs ATRA plus chemotherapy in newly diagnosed acute promyelocytic leukemia. First interim results of APL 93 trial. Blood 1997; 90(Supplement 1)122a
   Google Scholar
• Di Noto R., Schiavone E. M., Ferrara A. F., Manzo C., Lo Pardo C., Del Vecchio L. Expression and ATRA driven modulation of adhesion molecules in acute promyelocytic leukemia. Leukemia 1994; 8(Sup. 2)S71–76
   PubMedGoogle Scholar
• Di Noto R., Schiavone E. M., Ferrara A. F., Manzo C., Lo Pardo C., Del Vecchio L. All‐trans retinoic acid promotes a differential regulation of adhesion molecles on acute myeloid leukaemia blasts. Br J Haematol 1994; 88: 247–255
   PubMed Web of Science ®Google Scholar
• Di Noto R., Schiavone E. M., Lo Pardo C., Ferrara A. F., Manzo C., Vacca C., Del Vecchio L. Differential regulation of GPI‐linked molecules on leukaemic promyelocytes treated in vitro with all‐trans retinoic acid. Br. J Haematol. 1996; 93: 392–393
   PubMed Web of Science ®Google Scholar
• Marchetti M., Falanga A., Giovanelli S., Oldani E., Barbui T. All‐trans retinoic acid increases adhesion to endothelium of the human APML cell line NB4. Br. J. Haematol. 1996; 93: 360–366
   PubMed Web of Science ®Google Scholar
• Di Noto R., Lo Pardo C., Schiavone E. M., Ferrara A. F., Manzo C., Vacca C., Del Vecchio L. All‐trans retinoic acid and the regulation of adhesion molecles in acute myeloid leukemia. Leukemia & Lymphoma 1996; 21: 201–209
   PubMed Web of Science ®Google Scholar
• Brown D. C., Sklar L. A., Larson R. S. all‐trans retinoic acid alters selectin and integrin dependant adherence of the acute promyelocytic cell line NB‐4 under physiologic flow. Blood 1997; 90(Sup 1)415a
   Google Scholar
• Dubois C., Schlageter M. H., Gentile A., Balitrand N., Toubert M. E., Krawice I., Fenaux P., Castaigne S., Najean Y., Degos L., Chomienne C. Modulation of IL‐8, IL‐1b, and GCSF secretion by all trans retinoic acid in acute promyelocytic Leukemia. Leukemia 1994; 8: 1750–1757
   PubMed Web of Science ®Google Scholar
• Hurwitz A. A., Berman J. W., Lyman W. D. The role of the blood brain barrier in HIV infection of the central nervous. system Advances in Neuroimmunology 1994; 4: 249–256
   PubMedGoogle Scholar
• Umehara F., Izumo S., Takeya M., Takahashi K., Sato E., Osame M. Expression of adhesion molecules and monocyte chemoattractant protein‐1 (MCP‐1) in the spinal cord in HTLV—1‐associated myelopathy. Acta. Neuropathol 1996; 91: 343–350
   PubMed Web of Science ®Google Scholar
• Rossler K., Neuchrist C., Kitz K., Scheiner O., Kraft D., Lassman H. Expression of leucocyte adhesion molecules at the human blood brain barrier. J. Neurosciences Research 1992; 31: 365–374
   PubMed Web of Science ®Google Scholar
• Scott A. A., Kopecky K. J., Grogan T. M. CD56: A determinant of extramedullary and central nervous system involvement in acute myeloid leukemia. Proceedings of the United States and Canadian Academy of pathology meeting, San Francisco, CA, March, 12–181994
   Google Scholar
• Barclay A. N., Birkeland M., Brown M., Beyers A., Davis S., Somoza C., Williams A. F. The Leucocyte Antigen Factsbook. Academic Press. 1993; 104, Section II
   Google Scholar
• Shen Z. ‐X., Chen G. ‐Q., Ni J. ‐H., Li X. ‐S., Xiong S. ‐M., Qiu Q. ‐Y., Zhu J., Tang W., Sun G. ‐L., Yang K. ‐Q., Chen Y., Zhou L., Fang Z. ‐W., Wang Y. ‐T., Ma J., Zhang P., Zhang T. ‐D., Chen S. ‐J., Chen Z., Wang Z. ‐Y. Use of arsenic trioxide (AS2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354–3360
   PubMed Web of Science ®Google Scholar
• Lu D. ‐P., Qui J. ‐V., Chen S. ‐S., Lu X. ‐J. Effective treatment of AML‐M3 (APL) and their remission maintenance with Realgar: A pilot clinical and laboratory study on 38 patients. Blood 1997; 90(Sup. 1)416a
   Google Scholar